Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery.

NCT06772428 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors

Interventions

DRUG: Nano-crystalline Megestrol Acetate Oral Suspension
RADIATION: standard treatment

Sponsor

Changchun GeneScience Pharmaceutical Co., Ltd.